SCHEMBL4772450

SCHEMBL4772450

FC1(F)CCN(c2cc[c]cn2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.37
HSD17B10 Q99714 5/20 0.33
TSHR P16473 4/20 0.33
ALDH1A1 P00352 4/20 0.33
CYP2D6 P10635 3/20 0.33
CYP3A4 P08684 3/20 0.33
CYP2C19 P33261 3/20 0.33
HPGD P15428 2/20 0.33
CYP2C9 P11712 2/20 0.33
MAPK1 P28482 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
KMT2A Q03164 1/20 0.33
ADRA1A P35348 1/20 0.33
TRPV3 Q8NET8 1/20 0.33
PDE10A Q9Y233 1/20 0.32
HRH3 Q9Y5N1 3/20 0.32
LRRK2 Q5S007 4/20 0.32
PTGER4 P35408 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17610639 0.90 CACNA1H (0.36) HSD17B10ALDH1A1CYP3A4HPGDPDE10A
SCHEMBL17316550 0.82
SCHEMBL2067822 0.80 MAPT (0.36) CNR2TSHRALDH1A1SMN1; SMN2CYP1A2
SCHEMBL743397 0.80 MAPT (0.40) CNR2TSHRALDH1A1MAPK1SMN1; SMN2
SCHEMBL8206759 0.79 ALDH1A1 (0.44) HSD17B10TSHRALDH1A1HPGDMAPK1
SCHEMBL4778875 0.79 HRH3 (0.37) TSHRCYP2D6CYP3A4MEN1KMT2A
SCHEMBL1316269 0.78 MAPT (0.41) CNR2TSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL4778656 0.76
SCHEMBL8196832 0.75 HSD17B10 (0.40) HSD17B10TSHRALDH1A1CYP2D6CYP3A4
SCHEMBL4774184 0.75 OPRL1 (0.47) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
WO-2000023444-A1 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2000-04-27 WO claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2000023444-A1 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A CNR2 1507/4885HSD17B10 28/4885TSHR 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.